Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Final Results from Extension Studies

被引：4
|
作者：
Di Minno, Matteo Nicola Dario [1 ]
Minno, Alessandro Di [2 ]
Calcaterra, Ilenia [3 ]
Cimino, Ernesto [3 ]
Dell'Aquila, Francesco [3 ]
Franchini, Massimo [4 ]
机构：
[1] Univ Naples Federico II, Dept Translat Med Sci, Via S Pansini 5, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dipartimento Farm, Naples, Italy
[3] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[4] Carlo Poma Hosp, Dept Haematol & Transfus Med, Mantua, Italy
来源：
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2022年 / 48卷 / 02期
关键词：
D O I：
10.1055/s-0041-1740148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：253 / 255
页数：3
相关论文
共 50 条
  • [31] Safety and efficacy of a pegylated full-length recombinant factor VIII with extended half-life in previously treated children with hemophilia A
    Mullins, Eric
    Stasyshyn, Oleksandra
    Osman, Diana
    Liesner, Raina
    Wynn, Tung
    Alvarez-Roman, Maria-Teresa
    Engl, Werner
    Patrone, Lisa
    Sharkhawy, Marlies
    Abbuehl, Brigitt
    HAEMOPHILIA, 2016, 22 : 46 - 46
  • [32] Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
    Mueller, Jens
    Goldmann, Georg
    Marquardt, Natascha
    Poetzsch, Bernd
    Oldenburg, Johannes
    HAMOSTASEOLOGIE, 2020, 40 : S15 - S20
  • [33] Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia
    Morfini, Massimo
    Farrugia, Albert
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (10) : 883 - 892
  • [34] The half-life of infused factor VIII in patients with hemophilia A is influenced by ABO blood group.
    Vlot, AJ
    MauserBunschoten, EP
    Zarkova, AG
    Haan, E
    Kruitwagen, CLJJ
    Sixma, JJ
    vandenBerg, HM
    BLOOD, 1997, 90 (10) : 690 - 690
  • [35] IN-VIVO RECOVERY AND EARLY HALF-LIFE OF INFUSED FACTOR-VIII IN HEMOPHILIA-A
    KASPER, CK
    HAEMOPHILIA, 1995, 1 (01) : 14 - 16
  • [36] PK-guided switch from standard half-life to extended half-life factor VIII products
    Eduardo Megias-Vericat, Juan
    Bonanad, Santiago
    Martinez Garcia, Maria Fernanda
    Berrueco Moreno, Ruben
    Maria Mingot-Castellano, Eva
    Rodriguez Lopez, Manuel
    Canaro Hirnyk, Mariana
    Mateo Arranz, Jose
    Calvo Villas, Jose Manuel
    Haya, Saturnino
    Rosa Cid, Ana
    Iorio, Alfonso
    HAEMOPHILIA, 2020, 26 : 17 - 18
  • [37] The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
    Sun, Haowei
    Yang, Ming
    Poon, Man-Chiu
    Lee, Adrienne
    Robinson, K. Sue
    Sholzberg, Michelle
    Wu, John
    Iorio, Alfonso
    Blanchette, Victor
    Carcao, Manuel
    Klaassen, Robert J.
    Jackson, Shannon
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (07)
  • [38] Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice
    Sarafanov, Andrey G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [39] Evaluation of long-term prophylaxis with a pegylated full-length recombinant factor VIII with extended half-life in patients with hemophilia A
    Abbuehl, Brigitt
    Engl, Werner
    Patrone, Lisa
    Prener, Anne
    HAEMOPHILIA, 2016, 22 : 108 - 108
  • [40] Switch to extended half-life recombinant factor VIII FC in severe hemophilia A patients under prophylaxis. Experience in one centre
    Jimenez, R.
    Nunez, R.
    Jimenez, P.
    Rodriguez-Martorell, F. J.
    Perez-Simon, J. A.
    HAEMOPHILIA, 2018, 24 : 117 - 117
12345